Med2Date — Clinical Guidelines
Home Oncology Carcinoid Syndrome

Carcinoid Syndrome

Last updated 31 May 2026 · Oncology clinical guideline

📋 Key Information Summary

📋
  • Definition: Carcinoid syndrome is a paraneoplastic disorder caused by vasoactive substances — predominantly serotonin — released by neuroendocrine tumours (NETs), usually metastatic small-bowel (midgut) carcinoid tumours with hepatic metastases.
  • Epidemiology: Age-standardised incidence of gastroenteropancreatic NETs in Australia is approximately 5–7 per 100 000 per year; carcinoid syndrome complicates ~20–30 % of midgut NETs with liver metastases.
  • Classic triad: Episodic flushing (face, neck, trunk), secretory diarrhoea (often profuse), and right-sided cardiac valvular fibrosis (carcinoid heart disease).
  • Diagnosis: 24-hour urinary 5-HIAA (≥ 26 µmol/24 h in adults) remains the biochemical gold standard; serum chromogranin A supports diagnosis. Imaging with 68Ga-DOTATATE PET/CT (MBS item 61505 — Authority Required) is the preferred staging modality in Australia.
  • First-line symptom control: Somatostatin analogue (SSA) therapy — octreotide LAR 20 mg IM monthly or lanreotide Autogel 120 mg SC 28-dayly — controls flushing and diarrhoea in ~70 % of patients.
  • Surgical cure: Hepatic resection or cytoreductive surgery should be considered in patients with resectable liver metastases, as symptom control and survival benefit are well established.
  • Peptide receptor radionuclide therapy (PRRT): 177Lu-DOTATATE (Lutathera®) is PBS-listed (Authority Required) for progressive, somatostatin receptor–positive midgut NETs and improves progression-free survival.
  • Carcinoid heart disease: Echocardiography is mandatory at diagnosis; right-sided valvular fibrosis (tricuspid regurgitation, pulmonary stenosis) occurs in up to 50 % of patients with longstanding syndrome.
  • Carcinoid crisis prevention: IV octreotide 250–500 µg bolus pre-procedure/anaesthesia is essential to prevent life-threatening carcinoid crisis; avoid catecholamine-releasing agents.
  • Dietary modification: Avoid serotonin-rich foods (bananas, avocados, tomatoes, walnuts, plums) to reduce 5-HIAA production and diarrhoea severity.
  • Palliative symptom agents: Loperamide for breakthrough diarrhoea (PBS General Benefit); telotristat ethyl (Xermelo®) for refractory diarrhoea on SSA (not yet PBS-listed in Australia).
  • Multidisciplinary care: All patients require NET multidisciplinary team (MDT) review at a specialised centre (e.g., Royal North Shore Hospital Sydney, Peter MacCallum Cancer Centre Melbourne).
  • 5-year survival: Localised midgut NET 90–95 %; distant metastatic disease with carcinoid syndrome 50–60 %; carcinoid heart disease significantly worsens prognosis.

Introduction & Australian Epidemiology

Carcinoid syndrome is a paraneoplastic condition caused by the systemic release of vasoactive amines — most notably serotonin (5-hydroxytryptamine, 5-HT) — from well-differentiated neuroendocrine tumours (NETs). In Australia, gastroenteropancreatic NETs are the second most common gastrointestinal malignancy after colorectal cancer, with an age-standardised incidence of approximately 5–7 per 100 000 per year. The syndrome itself develops in roughly 20–30 % of patients with midgut (small-bowel) NETs that have metastasised to the liver, where vasoactive substances bypass first-pass hepatic metabolism.

Historically termed "carcinoid" (from the German karzinoide, meaning carcinoma-like), these tumours are now classified under the umbrella of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) by the WHO 2019 classification. The hallmark symptoms — episodic flushing, secretory diarrhoea, and right-sided cardiac valvular fibrosis — result from the direct pharmacological effects of serotonin, histamine, tachykinins, and prostaglandins on the cardiovascular, gastrointestinal, and pulmonary systems.

Australian data from the Australasian Gastro-Intestinal Trials Group (AGITG) and Cancer Council registries indicate that the median age at diagnosis is 55–65 years, with a slight female predominance. The small intestine (ileum) is the primary site in ~40 % of cases, followed by the appendix, lung, and rectum. Approximately 60–70 % of patients present with metastatic disease at diagnosis, underscoring the importance of early biochemical and imaging screening.

Management has evolved considerably with the introduction of somatostatin analogues, peptide receptor radionuclide therapy (PRRT), and targeted agents, shifting the paradigm from purely palliative symptom control toward disease modification. All patients should be managed through a specialised NET MDT in accordance with the eviQ NET protocols endorsed by Cancer Institute NSW.

Carcinoid Syndrome clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge — Carcinoid Syndrome: pathophysiology, clinical clues, diagnosis, imaging, and management.
Carcinoid Syndrome infographic, full size

Pathophysiology & Tumour Sites

Carcinoid tumours arise from enterochromaffin (EC) cells of the diffuse neuroendocrine system. The pathophysiology of carcinoid syndrome is primarily driven by the overproduction and systemic release of serotonin and other vasoactive mediators.

Serotonin Pathway

Tryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase, then decarboxylated to serotonin (5-HT) by aromatic L-amino acid decarboxylase. Serotonin is metabolised by monoamine oxidase (MAO) in the liver and lungs to 5-hydroxyindoleacetic acid (5-HIAA), which is renally excreted. In patients with hepatic metastases, serotonin enters the systemic circulation directly, bypassing hepatic first-pass metabolism and causing the clinical syndrome.

Other Vasoactive Substances

  • Histamine: Contributes to flushing and gastric acid hypersecretion.
  • Tachykinins (substance P, neurokinin A): Mediate bronchospasm and flushing.
  • Prostaglandins: Contribute to diarrhoea and flushing.
  • Kallikrein: Generates bradykinin, which causes vasodilation and flushing.

Primary Tumour Sites & Syndromic Associations

Primary Site % of All NETs Syndrome Association Venous Drainage
Small bowel (ileum) ~40 % Carcinoid syndrome (most common cause) Portal → hepatic (syndrome requires liver metastases)
Appendix ~25 % Rarely causes syndrome Portal
Lung (bronchial) ~25 % Carcinoid syndrome WITHOUT liver mets (drains to systemic circulation) Pulmonary → systemic
Rectum ~5 % Rarely causes syndrome Portal (inferior rectal → systemic, but small tumours)
Pancreas ~3 % Functioning syndromes (insulinoma, gastrinoma); non-functioning common Portal
⚠️
Key anatomical point: Bronchial carcinoid tumours can cause carcinoid syndrome without liver metastases because their venous drainage enters the systemic (pulmonary) circulation, bypassing hepatic metabolism of serotonin.

Carcinoid Heart Disease (Hedinger Syndrome)

Chronic serotonin exposure causes fibrosis of the right-sided cardiac valves (tricuspid and pulmonary), leading to tricuspid regurgitation and/or pulmonary stenosis. Left-sided valve involvement is uncommon because serotonin is metabolised during pulmonary transit. Up to 50 % of patients with longstanding carcinoid syndrome develop echocardiographic evidence of carcinoid heart disease.

Clinical Features (Flushing & Diarrhoea)

Carcinoid syndrome classically presents with a triad of flushing, diarrhoea, and right-sided cardiac valvular disease. Symptoms are often episodic, triggered by alcohol, stress, exercise, tyramine-rich foods, or catecholamines.

Flushing

  • Appearance: Episodic, deep red to violaceous erythema of the face, neck, and upper trunk; may last minutes to hours.
  • Triggers: Alcohol, emotional stress, spicy foods, certain medications (catecholamines, opioids).
  • Mechanism: Primarily mediated by serotonin, bradykinin, histamine, and substance P.
  • Mastocytosis differentiation: Carcinoid flushing is typically deeper red/violaceous and lacks urticaria or Darier sign seen in mastocytosis.

Diarrhoea

  • Character: Secretory, watery, often profuse (≥ 3–6 bowel motions/day); can be debilitating.
  • Mechanism: Serotonin increases gut motility and secretion; prostaglandins and tachykinins contribute.
  • Malabsorption: Chronic serotonin excess may cause fibrosis of mesenteric vessels leading to intestinal ischaemia and malabsorption.

Other Clinical Features

Feature Mechanism Frequency
Flushing Serotonin, bradykinin, histamine ~85 %
Diarrhoea Serotonin, prostaglandins ~75 %
Wheezing / bronchospasm Serotonin, tachykinins ~20 %
Right heart failure Serotonin-induced valvular fibrosis ~40–50 % (longstanding)
Pellagra (niacin deficiency) Tryptophan diverted to serotonin → niacin deficiency ~5 %
Mesenteric fibrosis Serotonin-induced desmoplasia ~30–40 %
🚨
Carcinoid crisis: Life-threatening exacerbation triggered by anaesthesia, surgery, or tumour manipulation. Presents with profound hypotension or hypertension, severe flushing, bronchospasm, tachyarrhythmias, and hyperglycaemia. Immediate IV octreotide 500 µg bolus is the emergency treatment. See Management section for perioperative prophylaxis.

Investigations (5-HIAA & Imaging)

Biochemical Investigations

Essential
24-hour urinary 5-HIAA
Gold standard for serotonin-producing NETs. Normal: < 26 µmol/24 h (adults). Sensitivity ~75 %, specificity ~100 % for midgut NETs. Avoid serotonin-rich foods and medications (acetaminophen, cough syrugs containing guaifenesin) for 72 hours before collection. Available at all major Australian pathology labs (Sonic, Healius). MBS item 66670.
Essential
Serum chromogranin A (CgA)
Elevated in > 80 % of NETs. Non-specific (also raised with renal failure, PPI use, atrophic gastritis). Useful for monitoring treatment response. MBS item 66839.
Available
Serum serotonin (5-HT)
Elevated in carcinoid syndrome. Less sensitive and more variable than 24-h urinary 5-HIAA. Useful when urine collection is impractical.
Available
Plasma neurokinin A (NKA)
Prognostic marker in midgut NETs. Elevated levels associated with worse survival. Not widely available in routine Australian practice.

Imaging Investigations

Essential
68Ga-DOTATATE PET/CT
Preferred somatostatin receptor (SSTR) imaging in Australia. Superior sensitivity (~95 %) to 111In-octreotide scintigraphy (OctreoScan). MBS item 61505 — Authority Required, restricted to patients with confirmed/probable NET or phaeochromocytoma. Performed at major PET centres (e.g., Royal Adelaide Hospital, Peter MacCallum, RPA Sydney).
Available
CT chest/abdomen/pelvis (with contrast)
First-line anatomical imaging. Identifies primary tumour, liver metastases, and mesenteric mass/fibrosis. MBS item 56800.
Available
MRI abdomen (liver protocol)
Superior to CT for detecting small liver metastases (< 1 cm). Recommended if CT equivocal or for surgical planning. MBS item 63501.
Available
Endoscopic ultrasound (EUS)
Excellent for pancreatic and duodenal NETs. Allows FNA biopsy. Available at tertiary centres.
Available
18F-FDG PET/CT
Reserved for poorly differentiated (high-grade, G3) NETs where SSTR expression may be low. MBS item 61501 — Authority Required.

Other Investigations

  • Transthoracic echocardiography (TTE): Mandatory at diagnosis to screen for carcinoid heart disease. Look for tricuspid valve thickening/restriction, pulmonary valve stenosis, and right heart failure. Repeat annually if syndrome is active.
  • Tissue biopsy / histopathology: WHO 2019 grading — G1 (Ki-67 < 3 %), G2 (Ki-67 3–20 %), G3 (Ki-67 > 20 %). Immunohistochemistry: synaptophysin+, chromogranin A+.
  • Baseline FBC, LFTs, renal function, HbA1c: To assess comorbidities and guide treatment dosing.

Management (Octreotide & Surgery)

Management of carcinoid syndrome requires a multimodal approach: symptom control with somatostatin analogues, disease-modifying therapy (surgery, PRRT), and treatment of complications (carcinoid heart disease, mesenteric fibrosis). All treatment decisions should be discussed at a NET MDT.

Somatostatin Analogues — First-Line Symptom Control

💊
Octreotide LAR
Sandostatin LAR® · Somatostatin analogue
Adult dose 20 mg deep IM injection every 28 days; titrate to 30 mg if inadequate symptom control
Short-acting rescue Octreotide 100–250 µg SC TDS for breakthrough symptoms during LAR initiation
Paediatric dose Limited data; specialist-guided dosing (1–10 µg/kg/day SC in divided doses)
Route Intramuscular (gluteal); short-acting SC
Renal adjustment No adjustment required
Hepatic adjustment Use with caution in severe hepatic impairment; reduce dose
PBS status ✔ PBS General Benefit
💊
Lanreotide Autogel
Somatuline Autogel® · Somatostatin analogue
Adult dose 120 mg deep SC injection every 28 days; may extend to every 56 days if stable on therapy for > 6 months (CLARINET extension data)
Route Subcutaneous (posterior upper arm, thigh, or buttock)
Renal adjustment No adjustment required
PBS status ✔ PBS General Benefit
ℹ️
SSA comparison: Octreotide LAR and lanreotide Autogel have equivalent efficacy for carcinoid syndrome symptom control. Choice depends on patient preference (IM vs SC injection), availability, and clinician familiarity. Both are PBS-listed as General Benefits in Australia.

Surgical & Locoregional Therapy

  • Primary tumour resection: Recommended for all resectable midgut NETs, even with distant metastases, to reduce tumour burden and prevent obstruction/mesenteric fibrosis.
  • Hepatic resection: Considered for patients with ≤ 3 liver metastases confined to one lobe (or bilobar if surgically feasible). Offers the best long-term symptom-free survival. Performed at specialised hepatobiliary centres.
  • Hepatic arterial embolisation (TAE) / chemoembolisation (TACE): For unresectable liver-dominant disease. TACE with doxorubicin or cisplatin can achieve symptom response in 50–80 %. Available at major centres.
  • Radiofrequency ablation (RFA) / microwave ablation: For small (< 3 cm), limited-number liver metastases. Can be combined with surgery.

Peptide Receptor Radionuclide Therapy (PRRT)

☢️
177Lu-DOTATATE
Lutathera® · Radiolabelled somatostatin analogue
Indication Progressive, well-differentiated (G1/G2), SSTR-positive midgut NETs with hepatic metastases
Regimen 7.4 GBq IV every 8 weeks × 4 cycles (with concurrent amino acid infusion for renal protection)
PBS status Authority Required — must meet PBS criteria (progressive SSTR+ midgut NET after SSA failure)

Carcinoid Crisis Prevention & Perioperative Management

1
Pre-procedure
Octreotide 250–500 µg IV bolus 30–60 minutes before anaesthesia induction or any procedure likely to manipulate the tumour. Continue octreotide infusion 50–200 µg/h IV throughout the procedure.
2
Intraoperative
Avoid catecholamine-releasing agents (epinephrine, norepinephrine) and direct-acting sympathomimetics. Use vasopressin or phenylephrine for hypotension. Have additional octreotide 500 µg IV available for bolus dosing.
3
Post-procedure
Continue octreotide infusion for 24–48 hours post-procedure. Monitor haemodynamics in high-dependency unit. Resume regular SSA dosing once stable.

Adjunctive & Supportive Therapies

Agent Indication Dose PBS
Loperamide Breakthrough diarrhoea 2 mg PO after each loose stool (max 16 mg/day) General Benefit
Codeine phosphate Refractory diarrhoea 15–30 mg PO QID PRN General Benefit
Telotristat ethyl (Xermelo®) Refractory diarrhoea on SSA (≥ 4 stools/day despite SSA) 250 mg PO TDS with food Not PBS-listed
Nicotinamide (niacin) Pellagra prevention (niacin deficiency) 100–300 mg PO daily Not PBS-listed (OTC)
Pancrelipase Malabsorption due to pancreatic insufficiency 25 000–50 000 lipase units PO with meals Restricted Benefit

Treatment Algorithm Summary

Step 1
Symptom Control
SSA (octreotide LAR 20 mg IM 28-dayly or lanreotide 120 mg SC 28-dayly) + dietary modification + loperamide PRN
Setting: Outpatient — NET MDT
Step 2
Disease Modification
Escalate SSA dose; consider PRRT (177Lu-DOTATATE), hepatic resection, or locoregional therapy (TACE/RFA) for progressive liver-dominant disease
Setting: Specialised NET centre
Step 3
Refractory / Progressive
Everolimus 10 mg PO daily (PBS Authority Required); telotristat ethyl for refractory diarrhoea; consider clinical trial; palliative care integration
Setting: Tertiary oncology centre

Special Populations

🤰 Pregnancy
Octreotide
Limited human data; use only if benefits outweigh risks. Not teratogenic in animal studies. Excreted in breast milk — avoid breastfeeding during treatment.
Lanreotide
Avoid in pregnancy; discontinue 2 months before planned conception. Animal data show embryo/fetal toxicity at high doses.
PRRT
Contraindicated in pregnancy. Effective contraception required during and for 6 months after treatment.
👶 Paediatrics
Epidemiology
Carcinoid syndrome in children is extremely rare. Most paediatric NETs are appendiceal and do not cause the syndrome. Bronchial carcinoid is the most common thoracic NET in children.
Octreotide
Paediatric dosing: 1–10 µg/kg/day SC in 2–4 divided doses. LAR formulation not studied in children < 18 years. Specialist paediatric oncology referral essential.
👴 Elderly
General
Majority of patients diagnosed > 55 years. Comorbid cardiac disease and polypharmacy are common. Cautious use of codeine for diarrhoea (sedation, constipation risk). Regular echocardiography for carcinoid heart disease surveillance.
🫘 Renal Impairment
Octreotide / Lanreotide
No dose adjustment required. Monitor 5-HIAA with caution as renal excretion may affect interpretation.
PRRT
Use with caution in eGFR < 30 mL/min; renal toxicity is a known adverse effect of 177Lu-DOTATATE. Concurrent amino acid infusion mandatory.
🫁 Hepatic Impairment
Octreotide
Reduced clearance in severe hepatic impairment; consider dose reduction and monitor for bradycardia, gallstones.
General
Hepatic metastases are the sine qua non of carcinoid syndrome. Liver function may be impaired by tumour burden; assess hepatic reserve before embolisation or surgery.
🛡️ Immunocompromised
General
PRRT causes transient lymphopenia and thrombocytopenia; monitor FBC. SSA therapy does not significantly affect immune function. No specific contraindications in immunocompromised patients, but infection risk should be considered with any interventional procedure.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Epidemiology
Limited population-level data exist on NET incidence in Aboriginal and Torres Strait Islander peoples. AIHW cancer data suggest gastrointestinal malignancies have a higher age-standardised incidence in First Nations Australians. NETs may be underdiagnosed due to delayed presentation and reduced access to specialist investigation.
Diagnostic access
68Ga-DOTATATE PET/CT is available only at major capital-city PET centres. Remote and very remote communities face significant barriers to accessing this essential staging modality. Telehealth-based NET MDT review and aeromedical retrieval (RFDS) should be used to facilitate timely diagnosis and staging.
Treatment access
SSA injections (octreotide LAR, lanreotide) require monthly clinic attendance, which is challenging in remote settings. Community health nurses and Aboriginal Health Workers can be trained to administer injections. PRRT requires travel to specialised nuclear medicine centres in capital cities.
Cultural considerations
Health literacy and culturally safe communication are essential. Involve Aboriginal Health Workers/Liaison Officers in all consultations. Respect sorry business and kinship obligations when scheduling follow-up. Provide translated patient information materials where available.
Follow-up
High rates of missed appointments in remote communities. Use patient recall systems via Aboriginal Community Controlled Health Organisations (ACCHOs). Consider extended-interval SSA dosing (e.g., lanreotide every 56 days) to reduce travel burden when stable.

📚 References

  1. 1. Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2012;61(1):1–22.
  2. 2. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135.
  3. 3. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233.
  4. 4. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and WHO expert consensus proposal. Mod Pathol. 2018;31(12):1770–1786.
  5. 5. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2021. Canberra: AIHW; 2021. Available from: www.aihw.gov.au.
  6. 6. Krug S, Boch M, Daniel HN, et al. Somatostatin analogues in the treatment of neuroendocrine tumours: past, present and future. Int J Mol Sci. 2012;13(10):12750–12768.
  7. 7. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663.
  8. 8. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004;90(10):1224–1228.
  9. 9. Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE PET/CT for detecting gastro-entero-pancreatic neuroendocrine tumours and unknown primary sites. J Clin Oncol. 2016;34(6):588–596.
  10. 10. Cancer Institute NSW. eviQ — Neuroendocrine tumours of the small intestine. Sydney: Cancer Institute NSW; 2024. Available from: www.eviq.org.au.
  11. 11. PBS Online. Pharmaceutical Benefits Scheme — Lutathera. Australian Government Department of Health; 2024. Available from: www.pbs.gov.au.
  12. 12. National Health and Medical Research Council (NHMRC). National Statement on Ethical Conduct in Human Research. Canberra: NHMRC; 2023.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).